What is the primary use of short-acting inhaled beta 2-agonists?

The primary use of short-acting inhaled beta 2-agonists is as a rescue inhaler for acute asthma attacks. These medications are designed to provide rapid relief from bronchospasm, which can occur during an asthma exacerbation. They work by stimulating the beta-2 adrenergic receptors in the bronchial smooth muscle, leading to bronchodilation and easing airway obstruction.

In situations where a patient experiences sudden difficulty breathing or an asthma attack, short-acting inhaled beta 2-agonists can quickly open the airways, allowing for better airflow and alleviating symptoms such as wheezing, chest tightness, and shortness of breath. Their rapid onset of action makes them ideal for emergency situations, distinguishing them from long-acting beta-agonists, which are intended for ongoing management and prevention of asthma symptoms.

Other options, such as daily maintenance of asthma or reducing inflammation, are associated with different types of medications, like inhaled corticosteroids or long-acting beta agonists, that address chronic symptoms and inflammation but are not suitable for immediate symptom relief. Preventing allergic reactions is similarly not a role of short-acting beta 2-agonists, as this function is more closely linked with antihistamines or other